You are here: Industry Insights > Market News > Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Erythorbic Acid (Molecular Formula:C₆H₈O₆)

Sodium Erythorbate(Molecular Formula:C₆H₇NaO₆·H₂O)

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

firstwordpharmaJuly 16, 2021

Tag: COVID-19 , Vaccine , CoronaVac

Favorites

The leaders of Chile’s late-stage human trial of Sinovac’s COVID-19 vaccine CoronaVac recommended a third dose of the shot, saying studies of participants showed their protecting antibody levels were lower after six months, as reported by Yahoo!News on Thursday.

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

According to the leaders, an in vitro trial to determine the shot’s effectiveness against the Delta variant of the virus showed a four-fold reduction in neutralizing effect against it, compared to a less severe, three-fold reduction previously reported by scientists in China.

Previous:TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections

Next:Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>